Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

terin levels occurred within the first cycle of custirsen treatment when compared to levels in the docetaxel arm, indicating on-target biological activity of custirsen; - Measurable stable disease was higher (77% in custirsen plus docetaxel arm versus 50% in docetaxel arm) and disease progression, without any response to therapy, was lower (4% in custirsen plus docetaxel arm versus 17% in docetaxel arm). The incidence of overall objective response was comparable; - Because the primary endpoint of the study was achieved and survival benefit was observed, custirsen warrants further study in Phase 3 trials.

"Despite the number of new treatment options for patients with advanced prostate cancer, many patients will eventually experience disease progression. We believe custirsen has the potential to reduce treatment resistance thereby increasing the efficacy of various therapeutic agents such as docetaxel, and are hopeful this will be confirmed through the Phase 3 development program," said Scott Cormack, president and CEO of OncoGenex.

In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen.

Phase 2 Study Design

In this Phase 2 study, 82 patients were randomized to one of two treatment arms to receive either 640 mg per week of custirsen by intravenous infusion in combination with docetaxel/prednisone or docetaxel/prednisone alone. Patients in both treatment arms received therapy until disease progression, toxicity or completion of ten 3-week cycles of therapy. The primary endpoint of the trial was to achieve a 50% reduction in PSA from baseline in over 50% of the patients treated with custirsen plus docetaxel. Secondary endpoints included determining objective response and duration of response in those patients with measurable disease at baseline, determining the tolerability and toxicity of weekly custirsen in combinati
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 02, 2015 Global Stem Cells Group ... for Bioquark, Inc.’s biologic products for the regeneration and repair ... in Global Stem Cells Group’s ambitious expansion plans in Latin ... for access to regenerative medicine and stem cell therapies. ... of biologics that have the ability to alter the regulatory ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ... Diagnostics - Global Market Size, Strategy and Forecasts - ... "Molecular Diagnostics - Global Market Size, Strategy and ... and planners can use. Hundreds of pages of information ... Medicare Fee Payment Schedules to help understand test pricing ...
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has ... Technology, Application & by Products - Global Forecast to ... global genotyping market is expected to reach $17.0 Billion ... CAGR of 22.3% during the forecast period of 2015 ... to the availability of a range of products for ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2
... Technology (QUT) researchers have developed new technology capable ... aiding clean-up efforts following nuclear disasters. The ... to clean up millions of tonnes of water ... the concentrated waste. Professor Huai-Yong Zhu from ...
... Cadence Pharmaceuticals, Inc. (NASDAQ: CADX ), a ... products principally for use in the hospital setting, today ... will present the company,s corporate overview on Wednesday, November ... during the Credit Suisse Healthcare Conference at the Arizona ...
... Axia Value Chain, a market leader in business ... of their Life Sciences and Health Care Practice Group. ... with global clients in the Health Care and Life ... services, practice development, and service offerings concentrating on alignment ...
Cached Biology Technology:Technology makes storing radioactive waste safer 2Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... RENO, Nev. Butterfly populations in California are declining and, ... Nevada due to climate change and loss of habitat, according ... of Nevada, Reno assistant professor in the College of Science. ... source for small mammals and birds," Forister said. "They play ...
... Would you pay more for certain products to ... carbon-offset industry proponents pay more money for carbon-producing ... carbon emissions will be balanced out by funding for ... climate scientists agree that a carbon tax would be ...
... are stunted, verging on the edge of survival. It ... conditions. A study published last week in Forest ... their genetic characteristics trees are unable to properly benefit ... surprised to find that the mortality of established trees ...
Cached Biology News:Climate change and habitat destruction affect butterfly populations 2You say offset, I say tax? Study suggests labels and political affiliation may affect preferences 2Northern forests do not benefit from lengthening growing season 2
Protein 3D structure prediction, via threading. Easy to use....
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
Biology Products: